BRPI0918806A2 - composição compreendendo quitosana para administração ocular de vaninas em aves - Google Patents

composição compreendendo quitosana para administração ocular de vaninas em aves

Info

Publication number
BRPI0918806A2
BRPI0918806A2 BRPI0918806A BRPI0918806A BRPI0918806A2 BR PI0918806 A2 BRPI0918806 A2 BR PI0918806A2 BR PI0918806 A BRPI0918806 A BR PI0918806A BR PI0918806 A BRPI0918806 A BR PI0918806A BR PI0918806 A2 BRPI0918806 A2 BR PI0918806A2
Authority
BR
Brazil
Prior art keywords
birds
chitosan
composition
ocular administration
vanines
Prior art date
Application number
BRPI0918806A
Other languages
English (en)
Inventor
Sylvain Comte
Vilmos Palya
Yannick Gardin
Original Assignee
Ceva Sante Animale Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Sante Animale Sa filed Critical Ceva Sante Animale Sa
Publication of BRPI0918806A2 publication Critical patent/BRPI0918806A2/pt
Publication of BRPI0918806B1 publication Critical patent/BRPI0918806B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição compreendendo quitosa para administração ocular de vacinas em aves. a presente invenção se refere a composições de vacina compreendendo quitosana e uma vacina que são administradas em espécies aviárias via rota ocular, e métodos ou programas de vacinação incluindo o uso da quisana para aumentar ou melhorar a imunudade mediada pela célula nas espécies aviárias e a persist~encia dos tecidos de aves de vacina.
BRPI0918806A 2008-09-05 2009-09-04 Composição de vacina compreendendo quitosana e antígeno do vírus de doença de newcastle (nvd) adaptada à administração ocular em ave, uso de quitosana e de nvd paraaumentar resposta imune em ave, bem como kit de vacinação de aves BRPI0918806B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9464208P 2008-09-05 2008-09-05
US16639809P 2009-04-03 2009-04-03
PCT/EP2009/061508 WO2010026239A1 (en) 2008-09-05 2009-09-04 Composition comprising chitosan for ocular administration of vaccine(s) to avians

Publications (2)

Publication Number Publication Date
BRPI0918806A2 true BRPI0918806A2 (pt) 2016-11-01
BRPI0918806B1 BRPI0918806B1 (pt) 2019-02-05

Family

ID=41259493

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918806A BRPI0918806B1 (pt) 2008-09-05 2009-09-04 Composição de vacina compreendendo quitosana e antígeno do vírus de doença de newcastle (nvd) adaptada à administração ocular em ave, uso de quitosana e de nvd paraaumentar resposta imune em ave, bem como kit de vacinação de aves

Country Status (9)

Country Link
US (1) US20110223195A1 (pt)
EP (1) EP2331128B1 (pt)
CN (2) CN103893758A (pt)
BR (1) BRPI0918806B1 (pt)
MX (1) MX2011002441A (pt)
PL (1) PL2331128T3 (pt)
RU (1) RU2498818C2 (pt)
WO (1) WO2010026239A1 (pt)
ZA (1) ZA201101552B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102423304B (zh) * 2011-11-24 2013-03-13 黑龙江大学 N-2-羟丙基三甲基氯化铵壳聚糖/n,o-羧甲基壳聚糖新城疫减毒活疫苗纳米粒的制备方法
CN102973936A (zh) * 2011-12-14 2013-03-20 普莱柯生物工程股份有限公司 壳聚糖在制备禽用疫苗组合物中的应用
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
CN102824635A (zh) * 2012-08-20 2012-12-19 上海生物制品研究所有限责任公司 壳聚糖作为佐剂在制备流感病毒减毒活疫苗中的应用
WO2014158963A1 (en) 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
EP2988777B1 (en) * 2013-04-24 2021-02-17 Medizinische Universität Wien Novel vaccine formulation for ocular immunization
WO2015116502A1 (en) * 2014-01-31 2015-08-06 The Regents Of The University Of California Detection and treatment of gnaq mutant uveal melanoma cells with gold nanoparticles
RU2583886C2 (ru) * 2014-02-28 2016-05-10 Пётр Евгеньевич Игнатов Мультипотентная вакцина для профилактики и лечения преимущественно инвазионных и инфекционных болезней, способ применения
CN104857013A (zh) * 2015-03-31 2015-08-26 中国科学院海洋研究所 一种抑制新城疫病毒的药物
CN107446858B (zh) * 2017-09-02 2020-11-03 河南省农业科学院畜牧兽医研究所 一株鸽支原体及其应用
CN114053295A (zh) * 2020-07-29 2022-02-18 以勒企业股份有限公司 几丁聚醣及其衍生物于抗微生物及抗病毒的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
CA2514667C (en) * 2003-01-30 2013-01-08 Chiron Corporation Adjuvanted influenza vaccine
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20080033398A1 (en) * 2005-12-29 2008-02-07 Transcutaneous Technologies Inc. Device and method for enhancing immune response by electrical stimulation

Also Published As

Publication number Publication date
MX2011002441A (es) 2011-05-19
CN102170904A (zh) 2011-08-31
WO2010026239A1 (en) 2010-03-11
ZA201101552B (en) 2012-05-30
EP2331128A1 (en) 2011-06-15
US20110223195A1 (en) 2011-09-15
CN103893758A (zh) 2014-07-02
EP2331128B1 (en) 2013-11-06
RU2011112932A (ru) 2012-10-10
PL2331128T3 (pl) 2014-06-30
RU2498818C2 (ru) 2013-11-20
BRPI0918806B1 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
BRPI0918806A2 (pt) composição compreendendo quitosana para administração ocular de vaninas em aves
NO20090062L (no) Influensavaksine
BR112014018815A8 (pt) Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis
IN2014DN08830A (pt)
AU2011280259A8 (en) Influenza vaccine
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
BR112012022669A2 (pt) composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112016015422A2 (pt) formulações de vacina de frasco único
BR112013026661A2 (pt) método de entrega de vacina
BR112015019126A2 (pt) Vacina de combinação para vírus sincicial respiratório e influenza
HRP20130065T1 (hr) Cjepivo protiv salmonele za perad
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
BR112015005056A2 (pt) vacinas de combinação com sorogrupo b meningococcus e d/t/p
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112015001313A2 (pt) composições de vacina
BR112013032410A2 (pt) composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
PE20151588A1 (es) Vacuna contra el virus del dengue
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
BRPI0910036B8 (pt) kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina
MX2026000391A (es) Vacunas de nanoparticulas multivalentes contra la influenza

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: CEVA SANTE ANIMALE SA (FR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2009, OBSERVADAS AS CONDICOES LEGAIS